Transgene Biotek opened higher at ₹2.78, compared with its previous close of ₹2.59. In the last trading session on 12 Nov 2026, the stock traded between ₹2.42 and ₹2.78, with an average traded price of ₹2.57. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Transgene Biotek is now worth
₹ 6,343.00
Resulting in a loss of
₹ 3,657.00 (36.57%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-0.04 (-1.54%)
Day High
₹2.78
Day Low
₹2.42
Day Open
₹2.78
Prev Close
₹2.59
Volume
16,948
Value Traded
₹0.00 Cr
1W Return
-0.78%
1M Return
3.24%
3M Return
-12.97%
6M Return
-20.31%
1Y Return
-31.27%
Market Cap (₹ Cr.)
19
PE Ratio
-12.30
PB Ratio
2.34
Dividend Yield
-
ROE
-6.74%
ROCE
-0.33%
Book Value (₹)
1.11
Face Value (₹)
10.00
EPS (TTM)
-0.05
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.78%
6 Weeks
-
1 Month
3.24%
3 Months
-12.97%
9 Months
18.06%
Transgene Q3FY26 Results: Cash at €84.3M, clinical progress noted
Cash and equivalents stood at €84.3 million as of September 30, 2026. Operating income for 9M 2026 was €4.3 million, driven by Research Tax Credits. TG4050 demonstrated 100% disease-free survival after 3 years in HNSCC trial. Financial visibility is confirmed through early 2028 under current plans.
3 days agoTransgene Biotek appoints Ranganath Prasad & Co after auditor quits in a day
Transgene Biotek appointed Ranganath Prasad & Co as statutory auditors on November 4, 2026. Previous auditor Harish Gummadi & Co resigned one day after appointment citing medical emergency. New appointment fills casual vacancy under Section 139(8) of Companies Act, 2013. Limited review for Q2FY27 remains due by November 14, 2026.
8 days agoTransgene to present PoxSTG-EEV preclinical data at SITC 2026
Transgene presents PoxSTG-EEV preclinical data at SITC 2026. Novel EEV formulation supports potential systemic IV delivery. Mouse models showed reduced tumor growth and prolonged survival. Data highlights resistance to immune-mediated neutralization.
9 days agoTransgene Biotek board to appoint Eswara Rao & Co as auditors
Transgene Biotek Ltd board meets October 10, 2026, to appoint new statutory auditors. Proposal involves M/s. Eswara Rao & Co. filling vacancy left by Vasavi & Co. Appointment subject to Audit Committee recommendation and shareholder approval.
1mo agoTransgene to meet institutional investors at Paris event on October 6
Transgene management will meet institutional investors at the Investor Access Event in Paris on October 6, 2026. The event connects over 190 professional investors with 90 listed companies through targeted meetings. Discussions will cover progress on TG4050 for head and neck cancer and TG4070 for non-small cell lung cancer. Transgene will also present updates on other virus-based programs from its emerging pipeline.
1mo agoTransgene H1FY26 Results: Net loss narrows 19% to €15.7 million
Net loss narrowed 18.8% YoY to €15.7 million in H1 2026. TG4050 Phase 1 data shows 100% disease-free survival after 3 years. Operating income fell 34.6% to €3.0 million due to lower tax credits. Cash position stands at €92.8 million with visibility until early 2028.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹8,579.50 | +0.76% | ₹1,23,360.05 | 52.40 | +14.42% | |
| ₹943.15 | -0.33% | ₹91,797.76 | 66.60 | -14.54% | |
| ₹685.65 | +1.35% | ₹90,188.84 | 98.20 | +16.21% | |
| ₹722.35 | -1.84% | ₹62,965.26 | 113.80 | +6.02% | |
| ₹762.00 | +0.26% | ₹57,527.81 | 54.00 | -21.39% | |
| ₹1,444.00 | +0.30% | ₹38,825.09 | 63.10 | +23.02% | |
| ₹1,852.40 | +0.67% | ₹37,855.80 | 43.70 | +5.30% | |
| ₹1,978.40 | -1.51% | ₹33,207.21 | 57.30 | +28.44% | |
| ₹723.80 | -0.48% | ₹30,400.07 | 155.10 | +5.30% | |
| ₹447.90 | +0.02% | ₹18,080.34 | 97.10 | -32.53% | |
| ₹554.50 | +0.59% | ₹17,579.10 | 85.10 | +8.49% | |
| ₹668.40 | +0.35% | ₹16,106.22 | 39.00 | +31.37% |
An investment of ₹10,000 made 5 years ago in Transgene Biotek is now worth
₹ 6,343.00
Resulting in a loss of
₹ 3,657.00 (36.57%)
Note: Past profits do not guarantee future returns.
